Patents by Inventor Ute Jaeger
Ute Jaeger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939395Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: June 9, 2021Date of Patent: March 26, 2024Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Publication number: 20210292431Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: ApplicationFiled: June 9, 2021Publication date: September 23, 2021Inventors: Michael TESAR, Ute JÄGER
-
Patent number: 11059902Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: September 7, 2018Date of Patent: July 13, 2021Assignee: MORPHOSYS AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 10865237Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).Type: GrantFiled: May 7, 2018Date of Patent: December 15, 2020Assignee: NOVARTIS AGInventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
-
Patent number: 10184005Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: October 8, 2015Date of Patent: January 22, 2019Assignee: MORPHOSYS AGInventors: Michael Tesar, Ute Jaeger
-
Publication number: 20180327486Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).Type: ApplicationFiled: May 7, 2018Publication date: November 15, 2018Applicant: Novartis AGInventors: Leslie Ngozi Anuna JOHNSON, Ute JAEGER, Yong-In KIM, Christian Carsten Silvester KUNZ, Igor SPLAWSKI, Michael ROGUSKA, Joy GHOSH, Barbara BRANNETTI, Michael STEFANIDAKIS, Sha-Mei LIAO
-
Patent number: 9988440Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).Type: GrantFiled: June 19, 2014Date of Patent: June 5, 2018Assignee: NOVARTIS AGInventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
-
Patent number: 9758590Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: GrantFiled: December 4, 2015Date of Patent: September 12, 2017Assignee: MORPHOSYS AGInventors: Michael Tesar, Ute Jaeger
-
Publication number: 20160200828Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: ApplicationFiled: March 31, 2016Publication date: July 14, 2016Inventors: Michael Tesar, Ute Jaeger
-
Publication number: 20160115243Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: ApplicationFiled: December 4, 2015Publication date: April 28, 2016Inventors: Michael Tesar, Ute Jaeger
-
Publication number: 20160096901Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: ApplicationFiled: December 4, 2015Publication date: April 7, 2016Inventors: Michael Tesar, Ute Jaeger
-
Publication number: 20160075796Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: ApplicationFiled: October 8, 2015Publication date: March 17, 2016Inventors: Michael Tesar, Ute Jaeger
-
Patent number: 9200061Abstract: The present invention provides methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: November 22, 2011Date of Patent: December 1, 2015Assignee: Morpho Sys AGInventors: Michael Tesar, Ute Jaeger
-
Patent number: 9193799Abstract: The present invention nucleic acids encoding novel antibodies and functional fragments thereof specific for CD38. Such antibodies are useful for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.Type: GrantFiled: June 14, 2013Date of Patent: November 24, 2015Assignee: MorphoSys AGInventors: Michael Tesar, Ute Jäger
-
Publication number: 20150158936Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).Type: ApplicationFiled: June 19, 2014Publication date: June 11, 2015Applicant: NOVARTIS AGInventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester KUNZ, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
-
Patent number: 9051365Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).Type: GrantFiled: December 17, 2012Date of Patent: June 9, 2015Assignee: Novartis AGInventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Sha-Mei Liao, Michael Stefanidakis
-
Publication number: 20140248265Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNy production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNy production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: March 20, 2014Publication date: September 4, 2014Applicant: NOVARTIS AGInventors: Michael Otto BARDROFF, Jose M. CARBALLIDO HERRERA, Daniela DELLA DUCATA, Christoph HEUSSER, Ute JAEGER, Christoph SCHWAERZLER
-
Patent number: 8715657Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: March 29, 2010Date of Patent: May 6, 2014Assignee: Novartis AGInventors: Michael Bardroff, Jose M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
-
Publication number: 20130295102Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).Type: ApplicationFiled: December 17, 2012Publication date: November 7, 2013Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti
-
Publication number: 20130273072Abstract: The present invention nucleic acids encoding novel antibodies and functional fragments thereof specific for CD38. Such antibodies are useful for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.Type: ApplicationFiled: June 14, 2013Publication date: October 17, 2013Inventors: Michael Tesar, Ute Jäger